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Abstract: Using a routine procedure, a number of derivatives of the benzo[4,5]isothiazolo[2,3-a]
pyrazine-6,6-dioxide ring system have been synthesized from readily available starting materials.
A series of chalcones were synthesized, which were subsequently reacted with chlorosulfonic
acid to generate chalcone sulfonyl chlorides. The chalcone sulfonyl chlorides were then treated
with bromine to generate dibromo chalcone sulfonyl chlorides. These were subsequently reacted
with 1,2-diaminopropane and 2-methyl-1,2-diaminopropane in boiling ethanol resulting in
compounds 2–10 and 11–19 respectively, in 12–80% yields. The products were characterized
by spectral analysis and the definitive structure of compound 11 was determined by X-ray
crystallography. The synthesized compounds were screened for potential antibacterial properties
against Bacillus subtilis, Escherichia coli, Proteus vulgaris and Staphylococcus aureus.
Keywords: chalcones; benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxides; Bacillus subtilis; Escherichia coli;
Proteus vulgaris; Staphylococcus aureus
1. Introduction
Antibacterial resistance has provoked an urgent need for novel antimicrobial agents. There has
been a significant decline in the number of new antibacterial agents being released onto the market [1].
Research by the Infectious Disease Society of America has stated that there needs to be a minimum of
ten new antimicrobial agents developed within the next eight years [2]. According to Theueretzbacher,
the development of antibacterial agents has slowed considerably, and the main research in developing
this group of drugs is being carried out in the pharma industry and academic institutions [3,4].
A possible reason for this could be that there are few targets available for selective toxic agents to act
on. The expected success of high-throughput screening and combinatorial libraries did not live up to
expectations [5]. The development of antimicrobial resistance has generated a huge demand for the
successful production of novel pharmaceutically active compounds.
Due to the emergence of superbugs, such as methicillin resistant Staphylococcus aureus (MRSA),
many antibiotics are no longer effective therapeutic agents. Although MRSA and vancomycin resistance
appears to be stabilizing, there are new problems occurring [6]. Heterocycles are an enormously diverse
group of compounds that are widely distributed in nature, and are found in many pharmaceuticals.
Heterocycles are easily manipulated in organic synthetic routes; the compounds can be easily modified
to increase or decrease reactivity [7]. Heterocycles are used extensively as intermediates in reactions and
Molecules 2017, 22, 1889; doi:10.3390/molecules22111889 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1889 2 of 11
as building blocks in synthesis. Benzoisothiazole 1 rings (see Figure 1) are found in many chemically
interesting compounds and derivatives of 1 have been synthesized. Derivatives of 1 have shown
varied biological activity [8].
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Figure 1. Structure of a benzo[d]isothiazole-1,1-dioxide 1.
Benzo[d]isothiazole combined with an arylidene moiety (a methylene derivative of an aryl group)
with a different substituent, such as a methyl group and a fluorine atom, have displayed cytotoxicity
against human CD4+ lymphocytes. These compounds inhibited the growth of leukemia cell lines and
also showed anti-proliferative activity against solid tumor-derived cell lines [8]. Vicini and colleagues
investigated benzoisothiazole hydrazone derivatives as possible antiviral agents. The investigation
focuse on the structural requirements that are ss tial for nti-HIV activity and how modifying
the alkene chain length b twee the benzoisothiazole ring and the hydr zone group would increase
or decrease any possible an i-HIV activity. Although many of the compounds did show promising
results, the mechanism of acti n remai s to be elucidated [9]. Benzothiazole derivatives have also been
found to inhibit human cyclooxygenase-2-enzymes (COX-2) [10].
Recent research in CNS-mediated diseases has given rise to discovery of a family of serotonin
(5-HT) receptors, 5-HT6. In vivo studies have shown that inhibition of 5-HT6 has a significant positive
impact on cognitive impairment. Sufferers from diseases such as Alzheimer’s and schizophrenia could
potentially have an effective treatment within the next decade [11–13]. In 2012, researchers synthesized
a group of benzoisothiazole derivatives that contained an N,N-dimethylformamide group, of which
two of the compounds displayed promising activity as potential 5-HT6 antagonists [14]. Chikalia
and colleagues synthesized a library of twenty benzimidazole-1,3,4-oxadiazole derivatives which
showed anti-tuberculosis activity at concentrations as low as 4 µg [15]. Pyrazine derivatives have
been extensively reviewed in the literature [16] and have displayed a wide range of antimicrobial
properties [17]. Pyrazine derivatives also play an important role in the food industry [18]. Recent
research on derivatives of bisbenzothiazolyl-pyridines and -pyrazine displayed strong antiproliferative
activity which has been uggested to work by exerting oxidative stress on the cancer cells [17].
2. Results and Discussion
The bi logical pro e ies of hete cycles, wh ch include nitrogen, oxygen and sulfur, have been
reported extensively over the l st fifty years [19]. The literature search reveal tha only a small
number of patents report synthetic routes to th isothiazolo[2,3-a]pyrazine ring system [20,21].
The synthesis started with by reacting 3,4-dimethoxybenzaldehyde with substituted acetophenones
following the known literature method to generate a number of chalcones [22]. The chalcones were
initially reacted with chlorosulfonic acid to yield the sulfonyl chlorides which were subsequently
reacted with bromine in glacial acetic acid resulting in the dibromochalcone sulfonyl chlorides.
These dibromochalcones were reacted with 1,2-diaminopropane and 2-methyl-1,2-diaminopropane to
afford benzo[4,5]isothiazolo[2,3-a]pyrazine derivatives 2–10 and 11–19 respectively.
The isolated products were identified on the basis of their spectral (IR, NMR and MS) data
as the respective benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide derivatives 2–19 (Scheme 1 and
Table 1). For example, the 1H-NMR spectrum of compound 12 showed a doublet at δ 7.86 and 7.19
with a coupling constant of 8.3 Hz, which is consistent with para substitution in the benzoyl ring.
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Two singlets were observed at δ 7.19 and δ 6.36 for the aromatic protons in the benzoisothiazole ring.
The two methoxy methyl protons appeared as singlets at δ 3.89 and δ 3.45 and the two methyl protons
of the pyrazine ring appeared as singlets at δ 1.39 and δ 1.22. The methine protons appeared at δ 3.64
and δ 2.94 as doublets with a coupling constant of 12.8 Hz, consistent with axial vicinal protons [23],
and the methylene hydrogens showed up at δ 4.55 and δ 4.47 as doublets with a coupling constant of
9.2 Hz.
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Table 1. Data for benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide derivatives 2–19.
Compound R1 R2 R3 R4 Yield (%) m.p. (◦C) m/z (M+)
2 H H H H 29 219–220 402.3
3 CH3 H H H 47 180–181 416.3
4 F H H H 30 181–182 420.2
5 Cl H H H 43 204–205 436.2
6 Br H H H 48 204–205 480.4
7 H Cl H H 79 194–195 436.2
8 H Br H H 50 189–190 482.7
9 H H Cl H 46 215–216 436.5
10 H H Br H 75 195–196 480.4
11 H H H CH3 34 163–164 416.3
12 CH3 H H CH3 64 205–206 430.3
13 F H H CH3 12 175–176 434.3
14 Cl H H CH3 39 180–181 450.2
15 Br H H CH3 45 195–196 494.1
16 H Cl H CH3 54 179–180 450.2
17 H Br H CH3 80 175–176 495.9
18 H H Cl CH3 64 191–192 450.2
19 H H Br CH3 29 201–202 498.6
Out of all the compounds, compound 7 was the only compound that inhibited the growth of all
the four bacteria tested. The growth of Escherichia coli, Proteus vulgaris and Staphylococcus aureus was
inhibited at a concentration of 1.6 mg·mL−1 or above (Table 2). As the concentration of compound 7
decreased from 1.6 mg·mL−1 down to the lowest concentration of 0.052 mg·mL−1 the inhibitory effect
of the compound decreased rapidly as seen by the increase in absorbance measured at 590 nm and
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. This compound also
showed activity against Bacillus subtilis, though the growth was inhibited at a lower concentration
(0.833 mg/mL) as shown by decrease in absorbance measured at 590 nm. Compound 7 had one
methyl group present on the fused pyrazine ring and a chlorine atom in the meta position on the
benzene ring. There was no visible trend or similarity in results that correlated to the number of
methyl groups on the pyrazine ring. There was no visible correlation between activity and halogen
present; however there is much evidence in the literature to support the potency enhancing effects of
halogen substituents [15]. The addition of halogens are frequently employed to increase antimicrobial
activity, however with the exception of compound 7, there was no significant difference in activity
when varying the substituent group.
3. Experimental Section
3.1. General Information
All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) and were used without
any further purification. Melting points were determined using a Gallenkamp melting point apparatus
(Thermo Fisher Scientific, Paisley, UK) and are uncorrected. The NMR spectra were recorded using
a 600 MHz spectrometer (JEOL Co. Ltd., Tokyo, Japan) with tetramethylsilane as the internal standard
and solvents as indicated. Chemical shifts were measured in ppm (δ) relative to TMS (0.00 ppm).
Coupling constants (J) are reported in Hertz (Hz). The following abbreviations are used to describe the
signal multiplicities: s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). LC-MS spectra
were obtained with a spectrometer equipped with an Electron Spray Ionisation (ESI) source (Varian:
210 LC pumps × 2, 1200 L Quadrapole MS/MS, 410 autosampler) (Varian (now Agilent), Oxford, UK)
using a gradient solvent system of A: Water/0.1% formic acid and B: acetonitrile/0.1% formic acid.
Infrared spectra were recorded with a Varian 800 FT-IR spectrophotometer (Varian) as KBr discs.
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3.2. Synthesis of Chalcones
The chalcones were synthesized by the well-established procedure using acetophenones and
3,4-dimethoxybenzaldehyde [22,24–28].
3.3. General Procedure for Synthesis of Chalcone Sulfonyl Chlorides
The chalcones (10 g; 0.032 mol) were added in portions to stirred chlorosulfonic acid (37.67 g;
0.32 mol) in an ice bath. After the addition was complete, the reaction mixture was left stirring at room
temperature. Progress of the reaction was monitored by thin layer chromatography (TLC) (Fisher
Scientific, Loughborough, UK When the reaction was complete (24 h), the mixture was poured slowly
over ice to remove excess chlorosulfonic acid. The sulfonyl chlorides were filtered by suction filtration
and washed with a cold water acetonitrile mixture. The resulting precipitate was considered pure
enough to be used in subsequent reactions by TLC analysis.
3.4. General Procedure for the Synthesis of Dibromo Chalcone Sulfonyl Chlorides
The crude chalcone sulfonyl chloride (10 g; 0.032 mol) was added to glacial acetic acid (125 mL)
with stirring. The resulting mixture was stirred at room temperature and to the stirred mixture was
added bromine (20.48 g; 0.13 mol) dissolved in 50 mL glacial acetic acid. The mixture was stirred until
a precipitate was formed, which was filtered and washed with cold glacial acetic acid.
3.5. General Method for Synthesis of Benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)(phenyl) Methanones (2–10)
To a stirred solution of the chalcone dibromo sulphonyl chloride (1 g) in ethanol (25 mL),
was added 1,2-diaminopropane (2 mole equivalent). The reaction mixture was warmed in a water
bath for 15 min until all the solids had dissolved. The reaction mixture was allowed to cool to
room temperature and the resulting solid was filtered and air dried. The product was purified by
recrystallization from ethanol.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(Phenyl)methanone (2). Yellow crystals; yield 29%; m.p. 219–220 ◦C. IR: (KBr ν cm−1) 3337 (NH);
1681 (C=O), 1287, 1176 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.15 (d, J = 6.42 Hz, 3 H), 2.79–2.88
(m, 1 H), 3.14–3.36 (m, 1 H), 3.48 (s, 3 H), 3.89 (s, 3 H), 3.90–3.94 (m, 1 H), 4.42 (d, J = 10.09 Hz, 1 H),
4.64 (d, J = 10.09 Hz, 1 H), 6.40 (s, 1 H), 7.21 (s, 1 H), 7.43 (t, J = 7.79 Hz, 2 H), 7.58 (t, J = 7.34 Hz, 1 H),
7.90 (d, J = 8.25 Hz, 2 H). 13C-NMR (CDCl3) δ ppm 18.90, 47.30, 48.29, 56.02, 56.40, 58.49, 62.49, 102.81,
107.34, 126.42, 127.87, 129.07, 129.17, 134.51, 135.54, 135.51, 150.47, 152.62, 198.30. MS (ESI m/z) 402.3
[M]+. Anal. Calcd. For: C20H22N2O5S: C, 59.69; H, 5.51. Found: C, 59.35; H, 5.60.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(p-tolyl)methanone (3). White crystals; yield 47%; m.p. 180–181 ◦C. IR: (KBr ν cm−1) 3447 (NH),
1663 (C=O), 1284, 1140 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.53 (d, J = 6.19 Hz, 3 H), 2.42 (m, 3 H),
3.13 (m, 1 H), 3.50 (d, J = 14.43 Hz, 1 H), 3.77 (dd, J = 14.43, 1.37 Hz, 1 H), 3.94 (s, 3 H), 3.98 (s, 3 H),
4.29 (d, J = 11.00 Hz, 1 H), 6.80 (s, 1 H), 7.26 (m, 3 H), 7.68 (d, J = 8.25 Hz, 2 H). 13C-NMR (151 MHz,
CDCl3) δ ppm 22.48, 38.76, 45.67, 55.47, 56.54, 56.67, 56.95, 102.97, 105.06, 123.14, 125.38, 126.06, 129.77,
130.15, 130.23, 133.17, 142.62, 150.81, 153.59, 166.65. MS (ESI m/z) 416.3 [M]+. Anal. Calcd. For:
C21H24N2O5S: C, 60.56; H, 5.81. Found: C, 60.60; H, 5.72.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(4-fluorophenyl)methanone (4). Yellow crystals; yield 30%; m.p. 181–182 ◦C. IR: (KBr ν cm−1) 3297 (NH),
1677 (C=O), 1290, 1144 (SO2). 1H-NMR (151 MHz, CDCl3) δ ppm 1.14 (d, J = 6.42 Hz, 3 H), 3.55 (s, 3 H),
3.89 (s, 3 H), 3.92 (dd, J = 14.67, 3.67 Hz, 1 H), 4.34 (d, J = 10.09 Hz, 1 H), 4.65 (d, J = 9.17 Hz, 1 H),
6.45 (s, 1 H), 7.10 (t, J = 8.71 Hz, 2 H), 7.21 (s, 1 H), 7.95 (m, 2 H). 13C-NMR (151 MHz, CDCl3) δ ppm
18.93, 47.40, 48.28, 56.25, 58.23, 59.07, 62.61, 102.86, 107.26, 116.21, 116.36, 126.47, 127.92, 131.92, 131.91,
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150.54, 152.70, 167.37, 196.74. MS (ESI m/z) 420.2 [M]+. Anal. Calcd. For: C20H21FN2O5S: C, 57.13; H,
5.03. Found: C, 57.23; H, 4.95.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(4-chlorophenyl)methanone (5). Yellow crystals; yield 43%; m.p. 204–205 ◦C. IR: (KBr ν cm−1) 3468 (NH),
1672 (C=O), 1284, 1142 (SO2); 1H-NMR (600 MHz, CDCl3) δ ppm 1.52 (d, J = 6.87 Hz, 3 H),
2.99 (dd, J = 14.43, 9.62 Hz, 1 H), 3.14 (dd, J = 14.78, 11.34 Hz, 1 H), 3.45 (d, J = 15.12 Hz, 1 H),
3.77 (dd, J = 14.43, 1.37 Hz, 1 H), 3.95 (m, 3 H), 3.98 (m, 3 H), 4.28 (d, J = 11.68 Hz, 1 H), 6.79 (s, 1 H),
7.25 (s, 1 H), 7.42 (m, 2 H), 7.73 (d, J = 8.25 Hz, 2 H). 13C-NMR (151 MHz, CDCl3) δ ppm 22.58, 38.68,
45.70, 55.54, 56.55, 56.66, 56.70, 102.93, 104.95, 115.69, 115.83, 126.04, 128.98, 129.03, 129.89, 136.72,
150.74, 153.53, 166.84. MS (ESI m/z) 436.2 [M]+. Anal. Calcd. For: C20H21ClN2O5S: C, 54.98; H, 4.84.
Found: C, 55.13; H, 4.75.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(4-bromophenyl)methanone (6). Yellow crystals; yield 48%; m.p. 204–205 ◦C. IR (KBr ν cm−1): 3458 (NH),
1672 (C=O), 1284, 1141 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.52 (d, J = 6.87 Hz, 3 H),
2.99 (dd, J = 14.43, 9.62 Hz, 1 H), 3.14 (dd, J = 14.78, 11.34 Hz, 1 H), 3.44 (d, J = 15.12 Hz, 1 H),
3.77 (d, J = 15.12 Hz, 1 H), 3.98 (m, 3 H), 3.98 (s, 3 H), 4.28 (d, J = 11.00 Hz, 1 H), 6.78 (s, 1 H),
7.25 (s, 1 H), 7.58 (d, J = 8.94 Hz, 2 H), 7.66 (m, 2 H). 13C-NMR (151 MHz, CDCl3) δ ppm 21.44, 22.63,
38.71, 45.73, 55.65, 56.28, 56.63, 102.89, 105.01, 126.01, 126.88, 129.47, 130.12, 137.88, 140.57, 150.66,
153.49, 167.93. MS (ESI m/z) 480.4 [M]+. Anal. Calcd. For: C20H21BrN2O5S: C, 49.90; H, 4.40. Found:
C, 49.85; H, 4.36.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(3-chlorophenyl)methanone (7). Light yellow crystals; yield 79%; m.p. 194–195 ◦C. IR (KBr ν cm−1):
1691 (C=O), 1270, 1158 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.53 (d, J = 6.87 Hz, 3 H),
3.00 (dd, J = 14.43, 9.62 Hz, 1 H), 3.44 (m, 1 H), 3.78 (dd, J = 14.43, 1.37 Hz, 1 H), 3.95 (s, 3 H),
3.99 (m, 3 H), 4.29 (d, J = 11.00 Hz, 1 H), 6.80 (s, 1 H), 7.25 (s, 1 H), 7.39 (m, 1 H), 7.43 (m, 1 H),
7.63 (m, 1 H), 7.78 (t, J = 1.72 Hz, 1 H). 13C-NMR (151 MHz, CDCl3) δ ppm 14.87, 41.86, 46.31, 56.54,
56.65, 56.78, 56.97, 67.41, 110.98, 111.87, 112.01, 112.30, 127.15, 129.00, 130.45, 131.31, 134.17, 134.27,
134.94, 135.44, 135.79, 149.16, 149.30, 154.75, 188.68. MS (ESI m/z) 436.2 [M]+. Anal. Calcd. For:
C20H21ClN2O5S: C, 54.98; H, 4.84. Found: C, 55.23; H, 4.92.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(3-bromophenyl)methanone (8). Yellow crystals; yield 50%; m.p. 189–190 ◦C. IR (KBr ν cm−1): 3455 (NH),
1686 (C=O), 1290, 1140 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.15 (d, J = 6.42 Hz, 3 H), 2.84 (m,
1 H), 3.27 (m, 1 H), 3.48 (s, 3 H), 3.89 (m, 3 H), 4.42 (d, J = 10.09 Hz, 1 H), 4.64 (d, J = 10.09 Hz, 1 H),
6.40 (s, 1 H), 7.21 (m, 1 H), 7.43 (t, J = 7.79 Hz, 2 H), 7.58 (t, J = 7.34 Hz, 2 H). 13C-NMR (151 MHz,
CDCl3) δ ppm 18.71, 47.37, 48.36, 58.32, 58.21, 58.54, 62.85, 102.91, 107.23, 123.45, 126.45, 127.78, 127.72,
127.82, 131.85, 132.20, 137.22, 150.59, 152.77, 197.14. MS (ESI m/z) 482.7 [M]+. Anal. Calcd. For:
C20H21BrN2O5S: C, 49.90; H, 4.40. Found: C, 49.80; H, 4.45.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(2-chlorophenyl)methanone (9). Yellow crystals; yield 46%; m.p. 215–216 ◦C. IR (KBr ν cm−1): 3388 (NH),
1683 (C=O), 1290, 1190 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.54 (d, J = 6.87 Hz, 3 H),
3.09 (dd, J = 14.43, 8.94 Hz, 1 H), 3.15 (dd, J = 14.78, 11.34 Hz, 1 H), 3.31 (d, J = 15.12 Hz, 1 H),
3.79 (d, J = 14.43 Hz, 1 H), 3.92 (s, 3 H), 3.94 (s, 3 H), 4.07 (m, 1 H), 4.66 (d, J = 11.00 Hz, 1 H),
7.24 (s, 1 H), 7.39 (d, J = 4.81 Hz, 2 H), 7.62 (d, J = 8.25 Hz, 2 H). 13C-NMR (151 MHz, CDCl3) δ ppm
22.54, 38.59, 45.68, 55.52, 56.55, 56.66, 56.83, 76.87, 77.08, 77.29, 102.97, 104.99, 126.09, 128.30, 128.96,
129.84, 136.51, 138.94, 150.79, 153.57, 166.84, 182.68, 182.36. MS (ESI m/z) 436.5 [M]+. Anal. Calcd. For:
C20H21ClN2O5S: C, 54.98; H, 4.84. Found: C, 55.10; H, 5.02.
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(2-bromophenyl)methanone (10). Yellow crystals; yield 75%; m.p. 195–196 ◦C. IR (KBr ν cm−1):
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3084 (NH), 1682 (C=O), 1286, 1123 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.15 (d, J = 6.42 Hz, 3 H),
3.59 (s, 3 H), 3.92 (dd, J = 14.67, 3.67 Hz, 1 H), 3.89 (s, 3 H), 3.92 (m, 1 H), 4.32 (d, J = 9.17 Hz, 1 H),
4.66 (d, J = 10.09 Hz, 1 H), 6.44 (s, 1 H), 7.21 (s, 1 H), 7.29 (t, J = 7.79 Hz, 1 H), 7.69 (d, J = 8.25 Hz,
1 H), 7.78 (d, J = 7.34 Hz, 1 H), 8.07 (s, 1 H). 13C-NMR (151 MHz, CDCl3) δ ppm 18.83, 47.27, 48.42,
56.15, 58.07, 62.80 (s), 102.92, 107.25, 123.45, 126.45, 127.75, 130.58, 131.85, 137.24, 150.61, 152.76, 197.03.
MS (ESI m/z) 480.4 [M]+. Anal. Calcd. For: C20H21BrN2O5S: C, 49.90; H, 4.40. Found: C, 50.10; H, 4.51.
3.6. General Method for Synthesis of Benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)(phenyl) Methanones (11–19)
To a stirred solution of chalcone dibromo sulphonyl chloride (1 g) in ethanol (25 mL), was added
2-methyl-1,2-diaminopropane (2 mole equivalent). The reaction mixture was warmed in a water
bath for 10–15 min until all the solids had dissolved. The reaction mixture was allowed to cool to
room temperature and the resulting solid was filtered and air dried. The product was purified by
recrystallization from ethanol.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(phenyl)methanone (11). White needle shaped crystals; yield 34%; m.p. 163–164 ◦C. IR (KBr ν cm−1):
3420 (NH), 1676 (C=O), 1277, 1141 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.24 (s, 3 H), 1.41 (s, 3 H),
2.96 (d, J = 12.84 Hz, 1 H), 3.46 (s, 3 H), 3.89 (s, 3 H), 3.66 (d, J = 12.84 Hz, 1 H), 3.78 (m, 1 H),
4.51 (m, 1 H), 4.59 (m, 1 H), 6.38 (s, 1 H), 7.22 (s, 1 H), 7.48 (m, 2 H), 7.61 (m, 1 H), 7.98 (d, J = 7.34 Hz,
2 H). 13C-NMR (151 MHz, CDCl3) δ ppm 16.98, 18.39, 33.43, 56.43, 56.59, 58.72, 71.70, 102.94, 104.95,
124.29, 125.66, 126.34, 127.99, 128.80, 129.20, 130.85, 131.49, 131.89, 131.97, 132.10, 135.72, 147.20, 153.35,
165.30, 192.55. MS (ESI m/z) 416.3 [M]+. Anal. Calcd. For: C21H24N2O5S: C, 60.56; H, 5.81. Found: C,
60.60; H, 5.82.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(p-tolyl)methanone (12). Light yellow crystals; yield 64%; m.p. 205–206 ◦C. IR (KBr ν cm−1): 3312 (NH),
1660 (C=O), 1275, 1177 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.22 (s, 3 H), 1.39 (s, 3 H), 2.40 (s, 3 H),
2.94 (d, J = 12.84 Hz, 1 H), 3.45 (s, 3 H), 3.64 (d, J = 12.84 Hz, 1 H), 3.89 (s, 3 H), 4.47 (d, J = 9.17 Hz, 1 H),
4.55 (m, 1 H), 6.36 (s, 1 H), 7.21 (s, 1 H), 7.25 (d, J = 8.25 Hz, 2 H), 7.86 (d, J = 8.25 Hz, 2 H). 13C-NMR
(151 MHz, CDCl3) δ ppm 20.23, 23.07, 28.32, 49.66, 49.95, 56.08, 56.44, 58.34, 58.52, 102.89, 106.71,
123.49, 126.89, 127.73, 130.64, 132.03, 137.24, 137.33, 150.66, 152.85, 197.35. MS (ESI m/z) 430.3 [M]+.
Anal. Calcd. For: C22H26N2O5S: C, 61.38; H, 6.09. Found: C, 61.30; H, 6.10.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(4-fluorophenyl)methanone (13). White crystals; yield 12%; m.p. 175–176 ◦C. IR (KBr ν cm−1): 3438 (NH),
1677 (C=O), 1289, 1180 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.24 (s, 3 H), 1.41 (s, 3 H), 3.54 (s, 3 H),
3.66 (d, J = 13.75 Hz, 1 H), 3.90 (s, 3 H), 4.44 (d, J = 10.09 Hz, 1 H), 4.61 (d, J = 9.17 Hz, 1 H), 6.42 (s, 1 H),
7.15 (t, J = 8.71 Hz, 2 H), 7.23 (s, 1 H), 8.03 (m, 2 H). 13C-NMR (151 MHz, CDCl3) δ ppm 23.06, 28.27,
49.89, 55.98, 56.44, 58.13, 58.43, 102.87, 106.74, 116.33, 116.47, 126.89, 132.00, 150.66, 152.78, 165.72,
167.43, 204.13. MS (ESI m/z) 434.3 [M]+. Anal. Calcd. For: C21H23FN2O5S: C, 58.05; H, 5.34. Found: C,
58.10; H, 5.30.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(4-Chlorophenyl)methanone (14). Light yellow crystals; yield 39%; m.p. 180–181 ◦C. IR (KBr ν cm−1):
3442 (NH), 1665 (C=O), 1290, 1182 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.22 (s, 3 H), 1.39 (s, 3 H),
2.93 (d, J = 12.84 Hz, 1 H), 3.55 (s, 3 H), 3.66 (d, J = 13.75 Hz, 1 H), 3.89 (s, 3 H), 4.41 (d, J = 9.17 Hz, 1 H),
4.59 (d, J = 9.17 Hz, 1 H), 6.41 (s, 1 H), 7.22 (s, 1 H), 7.44 (d, J = 9.17 Hz, 2 H), 7.93 (m, 2 H). 13C-NMR
(151 MHz, CDCl3) δ ppm 23.13, 28.36, 49.53, 49.97, 56.00, 56.43, 58.32, 58.41, 76.89, 77.10, 77.31, 102.86,
106.73, 126.90, 127.06, 129.47, 130.56, 133.87, 141.17, 150.62, 152.78, 197.41. MS (ESI m/z) 450.2 [M]+.
Anal. Calcd. For: C21H23ClN2O5S: C, 55.94; H, 5.14. Found: C, 55.90; H, 5.20.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(4-bromophenyl)methanone (15). Light yellow crystals; yield 45%; m.p. 195–196 ◦C. IR (KBr ν cm−1):
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3447 (NH), 1663 (C=O), 1290, 1182 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.22 (s, 3 H), 1.39 (s, 3 H),
2.93 (d, J = 13.76 Hz, 1 H), 3.55 (s, 3 H), 3.66 (d, J = 13.75 Hz, 1 H), 3.90 (s, 3 H), 4.40 (d, J = 9.17 Hz, 1 H),
4.59 (d, J = 9.17 Hz, 1 H), 6.41 (s, 1 H), 7.22 (s, 1 H), 7.61 (d, J = 9.17 Hz, 2 H), 7.84 (m, 2 H). 13C-NMR
(152 MHz, CDCl3) δ ppm 23.13, 28.35, 49.55, 49.97, 56.00, 56.44, 58.31, 58.40, 76.88, 77.10, 77.31, 102.86,
106.73, 126.89, 127.04, 129.98, 130.61, 132.48, 134.26, 150.62, 152.79, 197.63. MS (ESI m/z) 494.1 [M]+.
Anal. Calcd. For: C21H23BrN2O5S: C, 50.92; H, 4.68. Found: C, 50.95; H, 4.67.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(3-chlorophenyl)methanone (16). Light yellow crystals; yield 54%; m.p. 179–180 ◦C. IR (KBr ν cm−1):
3449 (NH), 1681 (C=O), 1275, 1190 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.24 (s, 3 H), 1.42 (s, 3 H),
2.95 (d, J = 13.75 Hz, 1 H), 3.58 (s, 3 H), 3.67 (d, J = 12.84 Hz, 1 H), 3.90 (s, 3 H), 4.41 (d, J = 9.17 Hz,
1 H), 4.61 (d, J = 9.17 Hz, 1 H), 6.42 (s, 1 H), 7.23 (s, 1 H), 7.42 (t, J = 7.79 Hz, 1 H), 7.58 (m, 1 H),
7.84 (d, J = 8.25 Hz, 1 H), 7.99 (t, J = 1.83 Hz, 1 H). 13C-NMR (151 MHz, CDCl3) δ ppm 23.05, 28.26,
49.91, 56.06, 56.44, 58.34, 58.48, 102.89, 106.70, 126.89, 127.31, 129.06, 130.43, 134.36, 137.14, 150.66,
152.84. MS (ESI m/z) 450.2 [M]+. Anal. Calcd. For: C21H23ClN2O5S: C, 55.94; H, 5.14. Found: C, 56.10;
H, 5.23.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(3-bromophenyl)methanone (17). Light yellow crystals; yield 80%; m.p. 175–176 ◦C. IR (KBr ν cm−1):
3447 (NH), 1681 (C=O), 1265, 1190 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.24 (s, 3 H), 1.42 (s, 3 H),
2.93 (m, 1 H), 3.70 (m, 1 H), 3.87 (s, 3 H), 3.90 (s, 3 H), 4.41 (d, J = 9.17 Hz, 1 H), 4.61 (d, J = 9.17 Hz,
1 H), 6.42 (s, 1 H), 7.23 (s, 1 H), 7.35 (t, J = 7.79 Hz, 1 H), 7.73 (d, J = 9.17 Hz, 1 H), 7.87 (d, J = 7.34 Hz,
1 H), 8.14 (t, J = 1.83 Hz, 1 H). 13C-NMR (151 MHz, CDCl3) δ ppm 21.84, 23.27, 28.42, 49.30, 50.01, 55.87,
56.40, 57.94, 58.89, 102.75, 106.84, 126.81, 127.22, 129.28, 129.83, 133.25, 145.75, 150.46, 152.64, 198.16.
MS (ESI m/z) 495.9 [M]+. Anal. Calcd. For: C21H23BrN2O5S: C, 50.92; H, 4.68. Found: C, 50.90; H, 4.60.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(2-chlorophenyl)methanone (18). White crystals; yield 64%; m.p. 191–192 ◦C. IR (KBr ν cm−1): 3448 (NH),
1720 (C=O), 1297, 1179 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.43 (s, 3 H), 1.57 (s, 3 H),
2.96 (dd, J = 16.05, 11.46 Hz, 1 H), 3.20 (d, J = 13.75 Hz, 1 H), 3.39 (m, 1 H), 3.67 (d, J = 14.67 Hz, 1 H),
3.92 (s, 3 H), 3.94 (s, 3 H), 4.63 (d, J = 11.00 Hz, 1 H), 6.75 (s, 1 H), 7.23 (s, 1 H), 7.32 (d, J = 2.75 Hz, 3 H),
7.40 (m, 1 H). 13C-NMR (151 MHz, CDCl3) δ ppm 23.26, 31.34, 42.19, 50.76, 56.54, 58.60, 60.05, 102.91,
104.78, 125.99, 127.55, 129.32, 129.70, 129.87, 130.01, 130.95, 143.44, 150.77, 153.75, 164.95. MS (ESI m/z)
450.2 [M]+. Anal. Calcd. For: C21H23ClN2O5S: C, 55.94; H, 5.14. Found: C, 55.92; H, 5.17.
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-a]pyrazin-1-yl)
(2-bromophenyl)methanone (19). White crystals; yield 29%; m.p. 201–202 ◦C. IR (KBr ν cm−1): 3467 (NH),
1715 (C=O), 1297, 1179 (SO2). 1H-NMR (600 MHz, CDCl3) δ ppm 1.43 (s, 3 H), 1.57 (s, 3 H),
2.95 (dd, J = 15.59, 11.92 Hz, 1 H), 3.21 (d, J = 13.75 Hz, 1 H), 3.36 (m, 1 H), 3.67 (d, J = 14.67 Hz,
1 H), 3.92 (s, 3 H), 3.93 (s, 3 H), 4.72 (d, J = 11.00 Hz, 1 H), 6.78 (s, 1 H), 7.23 (s, 1 H), 7.25 (m, 1 H),
7.29 (m, 1 H), 7.36 (m, 1 H), 7.59 (d, J = 8.25 Hz, 1 H). 13C-NMR (151 MHz, CDCl3) δ ppm 23.49,
31.11, 42.25, 50.81, 56.53, 58.88, 60.09, 76.88, 77.09, 77.30, 102.91, 104.76, 120.07, 125.96, 128.09, 129.33,
129.70, 130.09, 132.97, 145.30, 150.77, 153.77, 165.54. MS (ESI m/z) 498.6 [M]+. Anal. Calcd. For:
C21H23BrN2O5S: C, 50.92; H, 4.68. Found: C, 50.85; H, 4.75.
Supplementary materials: 1H- and 13C-NMR spectra for compounds 2 to 19; X-ray data for
compound 11.
3.7. Antimicrobial Activity
The benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide derivatives 2–19 were screened against
four bacteria, B. subtilis ATCC 6633, E. coli ATCC 25922, P. vulgaris ATCC 13315 (ATCC 29905) and
S. aureus ATCC 6538. The broth micro dilution method (with a slight modification as described by
the Clinical and Laboratory Standards Institute) using 96-well micro-titre plates was used to test the
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antibacterial activity of the compounds 2–19 [29]. The concentration of the compounds was tested in
a range of 6.67 mg·mL−1 down to 0.052 mg·mL−1. Dilutions were carried out so that each well had
50 µL of Mueller–Hinton broth with a particular concentration of the compound. An equal volume
of bacterial culture adjusted to 0.5 McFarland turbidity standard and further diluted to 1:20 was
added to the wells and incubated at 37 ◦C for 16–18 h. Plates were then examined for turbidity
as an indicator of growth, and the absorbance was taken using an ELISA reader at 590 nm [30].
The Minimum Inhibitiry Concentration (MIC) of the test compounds were further confirmed by adding
a concentration of 5 mg/mL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was
prepared in Phosphate Buffered Saline (PBS) (pH 7.2). Twenty µL of MTT solution was added to
each single well and the 96-well micro-titer plates were incubated for 30 min at 30 ◦C. The wells with
lowest concentration of the compound where there was no formazan were confirmed as the MIC of
the test compounds.
Streptomycin was used as a reference drug throughout all the antibacterial testing.
Table 2. MIC (µg/mL) of the compounds 2–19 against Gram Positive bacteria Bacillus. subtilis and
S Staphylococcus aureus and Gram negative bacteria Proteus vulgaris and Escherichia coli.
Compound S. aureus(MIC µg/mL)
B. subtilis
(MIC µg/mL)
E. coli
(MIC µg/mL)
P. vulgaris
(MIC µg/mL)
2 >1600 >1600 >1600 >1600
3 >1600 >1600 >1600 >1600
4 >1600 >1600 >1600 >1600
5 >1600 >1600 >1600 >1600
6 >1600 >1600 >1600 >1600
7 1600 833 1600 1600
8 >1600 >1600 >1600 >1600
9 >1600 >1600 >1600 >1600
10 >1600 >1600 >1600 >1600
11 >1600 >1600 >1600 >1600
12 >1600 >1600 >1600 >1600
13 >1600 >1600 >1600 >1600
14 >1600 >1600 >1600 >1600
15 >1600 >1600 >1600 >1600
16 >1600 >1600 >1600 >1600
17 >1600 >1600 >1600 >1600
18 >1600 >1600 >1600 >1600
19 >1600 >1600 >1600 >1600
Streptomycin 12.5 12.5 12.5 6.25
4. Conclusions
Using a routine procedure, the synthesis of a new series of benzo[4,5]isothiazolo[2,3-a]pyrazine-
6,6-dioxide derivatives starting from readily available chalcones was carried out. This methodology
is straightforward and the isolation of desired products is simple. Unfortunately, the synthesized
compounds displayed only weak or no antibacterial activity.
Supplementary Materials: Supplementary materials are available online (1H- and 13C-NMR spectra for
compounds 2 to 19; X-ray data for compound 11).
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